Evidence map›Paper›PMID 40657937›Full record

ArticleClinical pharmacology and therapeutics2025

Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™).

Paresh P Chothe, Andrea Whitcher-Johnstone, Aniruddha Karve, Diane Ramsden, Niresh Hariparsad

Abstract read
In one paragraph

Article in Clinical pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paresh P ChotheDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts, USA.ORCID 0000-0001-5661-9011
Andrea Whitcher-JohnstoneDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts, USA.
Aniruddha KarveDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts, USA.ORCID 0000-0002-1617-4828
Diane RamsdenDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts, USA.ORCID 0000-0003-2994-0728
Niresh HariparsadDrug Metabolism and Pharmacokinetics, Oncology Research and Development, AstraZeneca, Waltham, Massachusetts, USA.ORCID 0000-0002-6290-5329

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate prediction of oral drug absorption in humans is essential for early drug development; however, physiologically relevant human models are lacking. This study aims to comprehensively assess the EpiIntestinal™, a human primary intestinal 3D model, for its ability to predict oral absorption (F

Indexed as

Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersIntestinal AbsorptionModels, BiologicalAdministration, OralBiological AvailabilityCaco-2 CellsDrug InteractionsHumansIntestinal MucosaPermeabilityPharmaceutical PreparationsPregnane X ReceptorCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersPharmaceutical PreparationsPregnane X Receptor

Identifiers

PMID40657937
PMCPMC12641084

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.